semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ductal Breast Carcinoma in Situ Estrogen Receptor-negative Breast Cancer Estrogen Receptor-positive Breast Cancer HER2-negative Breast Cancer HER2-positive Breast Cancer Invasive Ductal Breast Carcinoma Invasive Lobular Breast Carcinoma Male Breast Cancer Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate Mucinous Ductal Breast Carcinoma Papillary Ductal Breast Carcinoma Progesterone Receptor-negative Breast Cancer Progesterone Receptor-positive Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Tubular Ductal Breast Carcinoma Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm) All radiographically suspicious lesions must be biopsied and have histologically confirmed ductal carcinoma in-situ, invasive ductal, invasive lobular, medullary, papillary, colloid (mucinous), or tubular histologies A maximum of two radiographically detected malignant lesions Clinical Stage I-II breast carcinoma, with lesion size =< 5 cm for the dominant mass and the second lesion detected only on MRI, treated with lumpectomies; the MRI detected lesion must be pathologically =< 1 cm Axillary lymph node evaluation, either sentinel lymph node biopsy or axillary dissection as deemed appropriate by the treating surgeon for all patients with invasive cancer; no axillary lymph node sampling is needed for patients with DCIS Negative resection margins with at least a 2 mm margin from invasive and in-situ cancer or a negative re-excision A posterior margin =< 2 mm from DCIS is permissible provided fascia was taken Patients are eligible regardless of estrogen receptor, progesterone receptor, or Her-2/neu amplification Hormonal therapy is allowed; if adjuvant chemotherapy is planned, the chemotherapy should be delivered first and radiation must begin no earlier than three weeks and no later than eight weeks following completion of chemotherapy Signed study-specific informed consent prior to study entry
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed breast cancer Metastatic disease amenable to biopsy Unresected tumor with no intention to undergo resection during study Archival tissue from the primary diagnosis or fresh biopsy from metastatic cancer site required Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.) Measurable disease only for phase II study Available tumor estrogen (ER), progesterone (PR), and HER2 status from metastatic site tested by IHC or FISH OR results from the original tumor diagnosis Any ER, PR, or HER2 level (positive or negative) acceptable (phase I) Triple-negative disease only (phase II) ER and PR negative defined as ≤ 1% by IHC
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed breast cancer T1c N1-2 or T2 N0-2 disease HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH) No prior systemic treatment regimens for breast cancer Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and hemoglobin 8g/dl) Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min Bilirubin level < 1.5 X ULN Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan) Karnofsky performance status 80% Age 18 years  Male patients Inflammatory or bilateral breast cancer Evidence of distant metastases Previous systemic or local treatment for breast cancer (including surgery, radiotherapy, cytotoxic and endocrine treatments) Past or current history of other neoplasms, except for Curatively treated non-melanoma skin cancer Adequately treated in situ carcinoma of the cervix Other cancer curatively treated and with no evidence of disease for at least 5 years Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension (resting diastolic blood pressure >115 mmHg), prior myocardial infarction, CHF, or other cardiomyopathy Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin  Patients not willing or unable to signed written consent form
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Breast Neoplasms Patient must be self-identified of Hispanic/Latino origin Patients must have histologically or cytologically confirmed diagnosis of breast cancer Age greater than or equal to 18 years Ability to understand and the willingness to sign a written informed consent document Must be willing and able to provide a saliva sample, answer questionnaire data online or complete a paper questionnaire, and request a copy of their pathology report  Males and subjects under the age of 18
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Estrogen Receptor-positive Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Patient must be ≥ 18 years of age Patient must be a postmenopausal woman, defined by one of the following Women ≥ 60 years Women aged 45-59 years with spontaneous cessation of menses ≥ 12 months prior to registration Women aged 45-59 years with cessation of menses of duration < 12 months or secondary to hysterectomy AND an follicle-stimulating hormone (FSH) level in the postmenopausal range according to institutional standards (or > 34.4 IU/L if institutional range is not available) prior to registration Women aged 45-59 years on hormonal replacement therapy who have discontinued hormonal therapy AND an FSH level in the postmenopausal range according to institutional standards (or > 34.4 IU/L if institutional range is not available) prior to registration Status post bilateral surgical oophorectomy Patient must have a negative serum pregnancy test within 48 hours before starting study treatment (if a woman of childbearing potential) Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2 Patient must have histologically or cytologically confirmed invasive breast cancer that is stage IV or metastatic (histologic/cytologic confirmation of recurrence preferred, but not required)  Patient must not have received prior treatment with a P13K inhibitor Patient must not have a known hypersensitivity to BKM120 or to its excipients Patient must not have untreated brain metastases; however, patients with metastatic central nervous system (CNS) tumors may participate in this trial if the patient is weeks from therapy completion (including radiation and/or surgery) Clinically stable at the time of study entry Not receiving corticosteroid therapy Patient must not have acute or chronic liver disease, renal disease, or pancreatitis Patient must not have any of the following mood disorders as judged by the Investigator or a Psychiatrist Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) Greater than or equal to Common Terminology for Adverse Events (CTCAE) grade 3 anxiety
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Ductal Carcinoma in Situ Must sign informed consent, witnessed, and dated prior to entry The participant has breast biopsy consistent with Ductal Carcinoma in situ (DCIS) Performance Status: ECOG 0-1 unless mobility is limited from chronic physical handicap No clinical evidence of other malignancies (except Basal Cell carcinoma) Complete blood count, differential and platelet count must be WNL or verified by the study chair to be related to conditions not interfering with normal health status Adequate hepatic and renal function (these must be WNL or verified by study chair to be related to conditions not interfering with normal health status) Normal fasting glucose No history of diabetes Medically and Psychologically able to comply with all study requirements Accessible for Follow up  Less than 21 years of age Known invasive breast cancer of any type Bilateral prophylactic mastectomy Prior malignancy of any type that occurred less than 5 years previously, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix Existing non-malignant disease that would preclude the administration of pasireotide Pregnancy: All subjects will have a beta-hCG serum pregnancy test to rule out pregnancy, a history will also be taken to make certain that recent sexual exposure does not put them at risk for pregnancy. If so a second serum pregnancy test will be done. Volunteers will be asked to use barrier contraception during study Tamoxifen or other preventive measures within 6 months Serious Psychiatric condition or addictive disorder Diabetes or elevated fasting blood sugar either by history or by HgbA1c greater than 6.5% or fasting serum glucose greater than 100mg/dL on screening labs. If fasting serum glucose is greater than 100mg/dL on screening labs, this test will be repeated to confirm the results Inability to inject medication or test for finger stick glucose
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Breast Cancer Diagnosis of invasive breast cancer or DCIS Appropriate for genetic testing, defined as if they meeting one or more of the following (note that patients may be appropriate for genetic testing even if they do not meet these but NCCN and most payers recognize these groups as clearly appropriate for testing) Must be a primary malignancy (not recurrence), but can be second diagnosis if is a contralateral cancer and the first cancer was not treated with mastectomy Female age ≥18 If Ashkenazi Jewish: Breast cancer diagnosis ≤ 60. Subjects will be presumed to be of Ashkenazi ethnicity if Jewish religious preference is confirmed in subject and at least 1 parent, unless they explicitly endorse Sephardic, Iranian, Yemeni/Ethiopian, or Bukharan Jewish Decent, in which case non-Ashkenazi will be applied. If not Ashkenazi Jewish Breast cancer diagnosis ≤ 45 OR Bilateral breast cancer, with first diagnosed ≤ 50 OR Breast cancer diagnosed at any age with a male relative with breast cancer OR Breast cancer diagnosis ≤ 50 with one or more of the following or more relative with breast cancer ≤ 50 or  LCIS without invasive cancer (IDC or ILC) and without DCIS Previous breast cancer treated with mastectomy Plan for neoadjuvant chemotherapy before surgery Unable to complete English language questionnaires, as instruments have not been validated in non-English speaking populations
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy. NOTE: Patients with lobular carcinoma, multifocal and/or multicentric ipsilateral breast cancer, multifocal calcifications, or ductal carcinoma in situ (DCIS) with microinvasion are NOT eligible. Patients with contralateral disease will remain eligible. 2. Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required. 3. Residual tumor size </= 2.0 cm in greatest diameter. Specifically, the tumor must measure </= 2.0 cm in the axis parallel to the treatment probe and </= 1.5 cm in the axis anti-parallel to the treatment probe. Largest size measured by mammogram, ultrasound or MRI will be used to determine eligibility. 4. Tumor enhancement on pre-registration MRI. 5. Tumor with <25% intraductal components in the aggregate. 6. Adequate breast size for safe cryoablation. Male breast cancer patients and female breast cancer patients with breasts too small to allow safe cryoablation are not eligible as the minimal thickness of the breast tissue does not lend itself to cryoablation. 7. Patients with prior in-situ or invasive breast carcinomas are eligible if the prior carcinomas occurred in the contralateral breast. Patients with prior in-situ or invasive carcinomas of the ipsilateral breast are not eligible  History of open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer. Note: Prior rotational and/or vacuum-assisted core biopsies are permitted if no significant distortion is seen on imaging that could obscure visualization and detection of residual disease on MRI, or visualization of cancer on ultrasound for cryoablation procedure. 2. Pregnant and/or lactating. Patients of childbearing potential must have a negative serum or urine pregnancy test. NOTE: Peri-menopausal women must be amenorrheic for > 12 months to be considered not of childbearing potential. 3. Patient has contra-indication to an MRI examination, such as clips/prostheses/implants that are not MRI compatible, or compromised renal function, with a measured or calculated glomerular filtration rate of 60ml/min/1.73m^2 4. Patients less than 18 years of age will not be included in this study
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Estrogen Receptor-positive Breast Cancer Invasive Ductal Breast Carcinoma Progesterone Receptor-positive Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Postmenopausal women Diagnosis of early stage, invasive ductal carcinoma (for which a lumpectomy or mastectomy is planned prior to systemic therapy) Estrogen receptor (ER)/progesterone receptor (PR) positive tumor (as confirmed by City of Hope Pathology Department if done on the outside) or Biopsy proven ER/PR positive tumor Ability to provide informed consent  Tumor that lacks both estrogen and progesterone receptors Patients who will receive neoadjuvant therapy prior to definitive surgery Bisphosphonate therapy currently or within the past 12 months Regular use of anti-inflammatory agents, with the exception of a baby aspirin regimen per principal investigator's (PI's) discretion Renal impairment as determined by a creatinine clearance < 60 ml/min as calculated by the Cockcroft-Gault formula using the patient's actual weight Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Secondary HER2 Positive Carcinoma of Breast All patients selected for this imaging study are patients scheduled to start trastuzumab-based therapy for advanced HER2 positive breast cancer (This includes trastuzumab alone, trastuzumab + chemotherapy, trastuzumab + endocrine therapy). 2. Histologically confirmed HER 2 positive (defined as FISH amplification ratio more than 2.2) invasive carcinoma of the breast (primary tumor at diagnosis) with locally recurrent or metastatic disease. 3. Patients with FDG-PET positive metastatic lesions. 4. Brain metastases are allowed provided they are controlled and they are not the sole site of metastatic disease. 5. Patient planned to have metastatic site biopsy for HER2 status control. 6. Age ≥ 18 years 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 8. For women of childbearing potential a pregnancy test will be done and an agreement to use a highly-effective non hormonal form of contraception. 9. Agreement from the patient to participate in this imaging study and if indicated agreement to biopsy one or two accessible lesions. 10. Signed written informed consent (approved by the Ethics Committee) obtained prior to any study procedure  Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) 2. Pregnant or lactating women 3. Current known infection with HIV, HBV, or HCV 4. Known severe hypersensitivity to trastuzumab 5. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol 6. Patients with bone only metastases are not eligible 7. Psychiatric illness/social situations that would limit compliance with study requirements 8. Patients who received lapatinib within the 7 days prior to HER immunoPET/CT